Document ID: EPA-HQ-OPP-2005-0258-0039
Agency: epa
Document Type: Supporting & Related Material
Title: 
Posted Date: 2006-08-30T04:00Z

Reader's
Guide:
Triadimefon
CRM:
John
W.
Pates,
Jr.
EPA/
OPPTS/
OPP/
SRRD
Reader's
Guide
to
the
Triadimefon
E­
Docket
#
OPP­
2005­
0258
Publication
Date:
August
30,
2006
EPA
has
created
this
document
to
provide
an
organizational
structure
to
the
Triadimefon
E­
docket.
The
docket
index
lists
the
caption
entries
sequentially,
while
this
document
lists
them
by
subject
matter.
The
Agency
is
providing
the
"
Readers
Guide"
to
allow
the
reader
to
more
easily
access
and
navigate
the
various
entries
contained
in
the
Triadimefon
E­
docket.

Phase
3
Federal
Register
and
Docket
Organizational
Documents:

Docket
Entry
1.
Federal
Register
Notification:
Triadimefon
and
Triadimenol
Reregistration
Eligibility
Decision
(
RED
for
Triadimefon
and
Tolerance
Reassessment
and
Risk
Management
Decision
(
TRED)
for
Triadimenol
Notice
of
Availability,
(
4­
Phase
Process)

Docket
Entry
2.
Reader's
Guide
to
Triadimefon:
EPA­
HQ­
OPP­
2005­
0258
Docket
Entry
3.
Triadimefon:
Revised
Acute,
Probabilistic
and
Chronic
Dietary
(
Food
+
Drinking
Water)
Exposure
and
Risk
Assessments
for
the
Triadimefon
Reregistration
 
D314778
Author:
Yvonne
Barnes
and
Sheila
Piper;
Health
Effects
Division
(
7509P)

Docket
Entry
4.
Triadimefon:
Response
to
Bayer
Public
Comments
Regarding
the
Environmental
Fate
and
Effects
Division
Triadimefon
Risk
Assessment
 
D328531
Author:
Fed
Jenkins
and
Jonathan
Angier;
Environmental
Fate
and
Effects
Division
(
75059P)

Docket
Entry
5.
Triadimefon:
Characterization
of
Triadimefon
Use
on
Golf
Courses,
Turf,
Pine
Sees
and
Seedling
Treatment,
and
Pineapple
 
D329823
and
D328572
Author
Jin
Kim,
Tara
Chandgoyal,
and
Jonathan
Becker;
Biological
and
Economic
Analysis
Division
(
750P)
Docket
Entry
6.
Triadimefon
+
Triadimenol:
Aggregate
Acute,
Chronic,
and
Short­
Term
Risk
Assessments
Reflecting
July,
2006
Risk
Mitigation
in
Response
to
the
Phase
4
Triadimefon
RED
D331455
Author:
Yvonne
Barnes
and
Sheila
Piper;
Health
Effects
Division
(
7509P)

Docket
Entry
7.
Triadimefon:
HED
Response
to
Comments
Received
During
the
Public
Comments
Phase
Author:
Richard
Griffin;
Health
Effects
Division
(
7509P)

Docket
Entry
8.
Triadimefon
/
Triadimenol:
Summary
of
Refinements
and
Revision
to
the
Human
Health
Risk
Assessment
 
D330611
Author:
Richard
Griffin;
Health
Effects
Division
(
7509P)

Docket
Entry
9.
Triadimefon:
Occupational
and
Residential
Exposure
Assessment
for
the
Reregistration
Eligibility
Decision
Document
 
D314814
and
D315040
Author
Shanna
Recore;
Health
Effects
Division
(
7509P)

Docket
Entry
10.
Triadimefon:
EPA/
FDA
Joint
Teleconference
on
July
11,
2006
to
Discuss
1,2,4
Triazole
(
Free
Triazole)
as
a
Common
Metabolite
of
Triazole
Derivative
Fungicides
and
Anastrozole,
Drug
Author:
Kimberly
Nesci;
Special
Review
and
Reregistration
Division
(
7508P)

Docket
Entry
11.
Triadimefon::
EFED
Revisions
to
the
Ecological
Risk
Assessment
(
dated
Aug.
30,
2005)
and
the
Drinking
Water
Exposure
Assessment
(
dated
Aug.
31,
2005)
in
Support
of
the
Triadimefon
Reregistration
Eligibility
Decision
Documents
 
D331725
Author:
Fed
Jenkins
and
Jonathan
Angier;
Environmental
Fate
and
Effects
Division
(
75059P)